Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques

Zdenek Hel, David Venzon, Monita Poudyal, Wen Po Tsai, Laura Giuliani, Ruth Woodward, Claire Chougnet, Gene Shearer, John D. Altman, David Watkins, Norbert Bischofberger, Alashle Abimiku, Phillip Markham, James Tartaglia, Genoveffa Franchini

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

Prolonged antiretrovirol therapy (ART) is not likely to eradicate human immunodeficiency virus type I (HIV-I) infection. Here we explore the effect of therapeutic immunization in the context of ART during primary infection using the simian immunodeficiency virus (SIV251) macaque model. Vaccination of rhesus macaques with the highly attenuated poxvirus-based NYVAC-SIV vaccine expressing structural genes elicited vigorous virus-specific CD4+ and CD8+ T cell responses in macaques that responded effectively to ART. Following discontinuation of a six-month ART regimen, viral rebound occurred in most animals, but was transient in six of eight vaccinated animals. Viral rebound was also transient in four of seven mock-vaccinated control animals. These data establish the importance of antiretroviral treatment during primary infection and demonstrate that virus-specific immune responses in the infected host can be expanded by therapeutic immunization.

Original languageEnglish
Pages (from-to)1140-1146
Number of pages7
JournalNature Medicine
Volume6
Issue number10
DOIs
StatePublished - Nov 2 2000
Externally publishedYes

Fingerprint

Immunization
Viremia
Macaca
Viruses
Animals
Infection
SAIDS Vaccines
Virus Diseases
T-cells
Therapeutics
Poxviridae
Simian Immunodeficiency Virus
Genes
Therapeutic Uses
Macaca mulatta
Vaccination
HIV
T-Lymphocytes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Hel, Z., Venzon, D., Poudyal, M., Tsai, W. P., Giuliani, L., Woodward, R., ... Franchini, G. (2000). Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nature Medicine, 6(10), 1140-1146. https://doi.org/10.1038/80481

Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. / Hel, Zdenek; Venzon, David; Poudyal, Monita; Tsai, Wen Po; Giuliani, Laura; Woodward, Ruth; Chougnet, Claire; Shearer, Gene; Altman, John D.; Watkins, David; Bischofberger, Norbert; Abimiku, Alashle; Markham, Phillip; Tartaglia, James; Franchini, Genoveffa.

In: Nature Medicine, Vol. 6, No. 10, 02.11.2000, p. 1140-1146.

Research output: Contribution to journalArticle

Hel, Z, Venzon, D, Poudyal, M, Tsai, WP, Giuliani, L, Woodward, R, Chougnet, C, Shearer, G, Altman, JD, Watkins, D, Bischofberger, N, Abimiku, A, Markham, P, Tartaglia, J & Franchini, G 2000, 'Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques', Nature Medicine, vol. 6, no. 10, pp. 1140-1146. https://doi.org/10.1038/80481
Hel, Zdenek ; Venzon, David ; Poudyal, Monita ; Tsai, Wen Po ; Giuliani, Laura ; Woodward, Ruth ; Chougnet, Claire ; Shearer, Gene ; Altman, John D. ; Watkins, David ; Bischofberger, Norbert ; Abimiku, Alashle ; Markham, Phillip ; Tartaglia, James ; Franchini, Genoveffa. / Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. In: Nature Medicine. 2000 ; Vol. 6, No. 10. pp. 1140-1146.
@article{9a010ec71cde438f980cd756e39249d4,
title = "Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques",
abstract = "Prolonged antiretrovirol therapy (ART) is not likely to eradicate human immunodeficiency virus type I (HIV-I) infection. Here we explore the effect of therapeutic immunization in the context of ART during primary infection using the simian immunodeficiency virus (SIV251) macaque model. Vaccination of rhesus macaques with the highly attenuated poxvirus-based NYVAC-SIV vaccine expressing structural genes elicited vigorous virus-specific CD4+ and CD8+ T cell responses in macaques that responded effectively to ART. Following discontinuation of a six-month ART regimen, viral rebound occurred in most animals, but was transient in six of eight vaccinated animals. Viral rebound was also transient in four of seven mock-vaccinated control animals. These data establish the importance of antiretroviral treatment during primary infection and demonstrate that virus-specific immune responses in the infected host can be expanded by therapeutic immunization.",
author = "Zdenek Hel and David Venzon and Monita Poudyal and Tsai, {Wen Po} and Laura Giuliani and Ruth Woodward and Claire Chougnet and Gene Shearer and Altman, {John D.} and David Watkins and Norbert Bischofberger and Alashle Abimiku and Phillip Markham and James Tartaglia and Genoveffa Franchini",
year = "2000",
month = "11",
day = "2",
doi = "10.1038/80481",
language = "English",
volume = "6",
pages = "1140--1146",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques

AU - Hel, Zdenek

AU - Venzon, David

AU - Poudyal, Monita

AU - Tsai, Wen Po

AU - Giuliani, Laura

AU - Woodward, Ruth

AU - Chougnet, Claire

AU - Shearer, Gene

AU - Altman, John D.

AU - Watkins, David

AU - Bischofberger, Norbert

AU - Abimiku, Alashle

AU - Markham, Phillip

AU - Tartaglia, James

AU - Franchini, Genoveffa

PY - 2000/11/2

Y1 - 2000/11/2

N2 - Prolonged antiretrovirol therapy (ART) is not likely to eradicate human immunodeficiency virus type I (HIV-I) infection. Here we explore the effect of therapeutic immunization in the context of ART during primary infection using the simian immunodeficiency virus (SIV251) macaque model. Vaccination of rhesus macaques with the highly attenuated poxvirus-based NYVAC-SIV vaccine expressing structural genes elicited vigorous virus-specific CD4+ and CD8+ T cell responses in macaques that responded effectively to ART. Following discontinuation of a six-month ART regimen, viral rebound occurred in most animals, but was transient in six of eight vaccinated animals. Viral rebound was also transient in four of seven mock-vaccinated control animals. These data establish the importance of antiretroviral treatment during primary infection and demonstrate that virus-specific immune responses in the infected host can be expanded by therapeutic immunization.

AB - Prolonged antiretrovirol therapy (ART) is not likely to eradicate human immunodeficiency virus type I (HIV-I) infection. Here we explore the effect of therapeutic immunization in the context of ART during primary infection using the simian immunodeficiency virus (SIV251) macaque model. Vaccination of rhesus macaques with the highly attenuated poxvirus-based NYVAC-SIV vaccine expressing structural genes elicited vigorous virus-specific CD4+ and CD8+ T cell responses in macaques that responded effectively to ART. Following discontinuation of a six-month ART regimen, viral rebound occurred in most animals, but was transient in six of eight vaccinated animals. Viral rebound was also transient in four of seven mock-vaccinated control animals. These data establish the importance of antiretroviral treatment during primary infection and demonstrate that virus-specific immune responses in the infected host can be expanded by therapeutic immunization.

UR - http://www.scopus.com/inward/record.url?scp=0033786575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033786575&partnerID=8YFLogxK

U2 - 10.1038/80481

DO - 10.1038/80481

M3 - Article

VL - 6

SP - 1140

EP - 1146

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 10

ER -